FLOW Trial Deep Dive: Semaglutide's 24% Kidney Disease Risk Reduction

The first dedicated kidney outcomes trial for a GLP-1 receptor agonist. 3,533 participants, 28 countries, stopped early for efficacy. Complete data analysis with subgroup outcomes.

FLOW (NCT03819153) is the first dedicated kidney outcomes trial evaluating a GLP-1 receptor agonist. The trial was initiated in 2019, stopped early in October 2023 for overwhelming efficacy, and published in the New England Journal of Medicine in 2024. It represents the strongest evidence to date that GLP-1 medications have direct kidney-protective effects beyond weight loss.

Trial Design

FLOW was a double-blind, randomized, placebo-controlled, event-driven superiority trial comparing injectable semaglutide 1.0 mg once weekly with placebo as an adjunct to standard of care. The median follow-up was 3.4 years.

Enrollment criteria: Type 2 diabetes with chronic kidney disease, defined as eGFR 50–75 mL/min/1.73 m² with UACR >300 or eGFR 25–50 mL/min/1.73 m² with UACR >100. This captured patients across a broad spectrum of CKD severity, including advanced disease.

Population: 3,533 participants (1,767 semaglutide, 1,766 placebo) enrolled at approximately 400 sites across 28 countries. Mean age 66 years, 30% women, mean HbA1c 7.8%, mean BMI 32, mean eGFR 47 mL/min/1.73 m². Diabetes duration averaged >15 years. 23% had prior stroke. 93% were at high or very high risk of CKD progression.

Primary Endpoint Results

Key findings across endpoints:

Subgroup Analyses: CKD Severity

A February 2026 subgroup analysis published in CJASN examined outcomes by baseline eGFR and albuminuria strata. The key finding: semaglutide reduced risks of major kidney disease events and all-cause death across all categories of baseline CKD severity, including advanced CKD (eGFR 25–50 mL/min/1.73 m²).

This is clinically significant because prior GLP-1 cardiovascular outcome trials had suggested benefits were concentrated in patients with eGFR ≥60 — FLOW demonstrates the benefit extends to sicker kidneys.

Mechanistic Considerations

GLP-1 receptors are expressed in the kidney. The proposed mechanisms for renal protection:

• Reduction in hyperfiltration: Decreased intraglomerular pressure, reducing nephron workload
• Anti-inflammatory effects: GLP-1R activation reduces renal inflammation and oxidative stress
• Glycemic and metabolic improvement: Indirect benefits through improved glucose control and weight loss
• Blood pressure reduction: Natriuretic effects of GLP-1R activation

Notably, 15.6% of FLOW participants were already taking SGLT2 inhibitors — another kidney-protective drug class. Semaglutide showed additive benefit on top of SGLT2i therapy, supporting combination use.

Clinical Implications

The 2026 ADA Standards of Care now recommend GLP-1 agonists or SGLT2 inhibitors as first-line therapy for T2D with cardiovascular or kidney disease risk. FLOW provides the trial evidence that specifically supports the kidney indication for semaglutide. This shifts GLP-1 therapy from a weight-loss intervention with metabolic side benefits to a direct organ-protective therapy with weight loss as an additional benefit.